Furthermore, during bone metastasis in breast cancer, CaSR promotes the adaptation of cancer cells to the bone microenvironment (Organista-Juarez et al., 2013), while CaSR antagonists may reduce the capacity of tumor cells to invade bone by reducing Ca2+ dependent signaling. This evidence concerns the gene CASR and breast cancer.